Palvella Therapeutics PVLA Increase Decrease In Research And Development Tax Credit Receivables
Increase Decrease In Research And Development Tax Credit Receivables at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivables.
The official record: Palvella Therapeutics’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's increase decrease in research and development tax credit receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's increase decrease in research and development tax credit receivables?
- Palvella Therapeutics (PVLA) reported increase decrease in research and development tax credit receivables of -$526.25K in Q4 2025.
- How has Palvella Therapeutics's increase decrease in research and development tax credit receivables changed year-over-year?
- Palvella Therapeutics's increase decrease in research and development tax credit receivables decreased by 206.4% year-over-year, from $494.5K to -$526.25K.
- What does increase decrease in research and development tax credit receivables mean?
- Measures the change in receivables related to tax credits earned from research and development activities. An increase indicates that the company has accrued tax benefits that are expected to be collected in future periods, effectively reducing the net cost of R&D. This metric is a key indicator of the company's ability to leverage government incentives to offset innovation-related expenditures.